Myth: Alternative nicotine products are as dangerous as smoking: Difference between revisions
Jump to navigation
Jump to search
| Line 297: | Line 297: | ||
*Citation: Polosa R, Morjaria JB, Prosperini U, Russo C, Pennisi A, Puleo R, Caruso M, Caponnetto P. Health effects in COPD smokers who switch to electronic cigarettes: a retrospective-prospective 3-year follow-up. Int J Chron Obstruct Pulmon Dis. 2018;13:2533-2542 https://doi.org/10.2147/COPD.S161138 | *Citation: Polosa R, Morjaria JB, Prosperini U, Russo C, Pennisi A, Puleo R, Caruso M, Caponnetto P. Health effects in COPD smokers who switch to electronic cigarettes: a retrospective-prospective 3-year follow-up. Int J Chron Obstruct Pulmon Dis. 2018;13:2533-2542 https://doi.org/10.2147/COPD.S161138 | ||
===2017: E-cigarettes in patients with COPD: current perspectives=== | ===2017: [http://E-cigarettes%20in%20patients%20with%20COPD:%20current%20perspectives E-cigarettes in patients with COPD: current perspectives]=== | ||
*Although ECs are not risk free, they are much less harmful than conventional tobacco smoking. The emerging clinical evidence suggests that ECs are unlikely to raise significant health concerns for the respiratory tract under normal conditions of use, even in smokers with preexisting lung disease. In particular, recent studies in COPD and chronic asthma suggest that substitution of conventional tobacco cigarettes for ECs can ameliorate subjective and objective disease-related outcomes and exacerbation rates as well as improving success in abstaining from smoking long term. | |||
Although ECs are not risk free, they are much less harmful than conventional tobacco smoking. The emerging clinical evidence suggests that ECs are unlikely to raise significant health concerns for the respiratory tract under normal conditions of use, even in smokers with preexisting lung disease. In particular, recent studies in COPD and chronic asthma suggest that substitution of conventional tobacco cigarettes for ECs can ameliorate subjective and objective disease-related outcomes and exacerbation rates as well as improving success in abstaining from smoking long term. | *[https://acrobat.adobe.com/link/track?uri=urn%3Aaaid%3Ascds%3AUS%3Aaa3f75b1-853a-484c-b692-f9ca7a5ee2d2&viewer%21megaVerb=group-discover PDF] | ||
*Morjaria JB, Mondati E, Polosa R. E-cigarettes in patients with COPD: current perspectives. Int J Chron Obstruct Pulmon Dis. 2017;12:3203-3210 | |||
https://doi.org/10.2147/COPD.S135323 | |||
===2017: Reduced biological effect of e-cigarette aerosol compared to cigarette smoke evaluated in vitro using normalized nicotine dose and RNA-seq-based toxicogenomics=== | ===2017: Reduced biological effect of e-cigarette aerosol compared to cigarette smoke evaluated in vitro using normalized nicotine dose and RNA-seq-based toxicogenomics=== | ||